APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Inhibitors for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global VEGF Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025199 pages

Choose your research edition.

Industry ResearchVEGF Inhibitors for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Inhibitors for Cancer Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal VEGF Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Inhibitors for Cancer Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Inhibitors for Cancer Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global VEGF Inhibitors for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for VEGF Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VEGF Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGF Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for VEGF Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of VEGF Inhibitors for Cancer include Amgen, Amneal Pharmaceuticals, Celltrion Healthcare, Eli Lilly, Pfizer, Roche, Sanofi, Boan Biotech and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VEGF Inhibitors for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VEGF Inhibitors for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VEGF Inhibitors for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VEGF Inhibitors for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

VEGF Inhibitors for Cancer Segment by Company

Amgen

Amneal Pharmaceuticals

Celltrion Healthcare

Eli Lilly

Pfizer

Roche

Sanofi

Boan Biotech

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

VEGF Inhibitors for Cancer Segment by Type

Ramucirumab

Ramucirumab

Aflibercept

Other

VEGF Inhibitors for Cancer Segment by Application

Metastatic colorectal cancer

Metastatic Non-small Cell Lung Cancer

Cervical Cancer

Recurrent Glioblastoma

Other

VEGF Inhibitors for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitors for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VEGF Inhibitors for Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of VEGF Inhibitors for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of VEGF Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of VEGF Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. VEGF Inhibitors for Cancer Industry Trends Table 2. VEGF Inhibitors for Cancer Industry Drivers Table 3. VEGF Inhibitors for Cancer Industry Opportunities and Challenges Table 4. VEGF Inhibitors for Cancer Industry Restraints Table 5. Global VEGF Inhibitors for Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global VEGF Inhibitors for Cancer Revenue Market Share by Manufacturers (2021-2026) Table 7. Global VEGF Inhibitors for Cancer Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers Table 9. Global VEGF Inhibitors for Cancer Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global VEGF Inhibitors for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global VEGF Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global VEGF Inhibitors for Cancer Manufacturers, Product Type & Application Table 13. Global VEGF Inhibitors for Cancer Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global VEGF Inhibitors for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ramucirumab Table 17. Major Manufacturers of Ramucirumab Table 18. Major Manufacturers of Aflibercept Table 19. Major Manufacturers of Other Table 20. Global VEGF Inhibitors for Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 22. Global VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 23. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2026) Table 24. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2027-2032) Table 25. Global VEGF Inhibitors for Cancer Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (K Units) Table 27. Global VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (K Units) Table 28. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2026) Table 29. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Metastatic colorectal cancer Table 31. Major Manufacturers of Metastatic Non-small Cell Lung Cancer Table 32. Major Manufacturers of Cervical Cancer Table 33. Major Manufacturers of Recurrent Glioblastoma Table 34. Major Manufacturers of Other Table 35. Global VEGF Inhibitors for Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 37. Global VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 38. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2026) Table 39. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2027-2032) Table 40. Global VEGF Inhibitors for Cancer Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (K Units) Table 42. Global VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (K Units) Table 43. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2026) Table 44. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2027-2032) Table 45. Global VEGF Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global VEGF Inhibitors for Cancer Sales by Region (2021-2026) & (K Units) Table 47. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021-2026) Table 48. Global VEGF Inhibitors for Cancer Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global VEGF Inhibitors for Cancer Sales Forecasted Market Share by Region (2027-2032) Table 50. North America VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 52. North America VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 53. Europe VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 55. Europe VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 62. Global VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global VEGF Inhibitors for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 64. Global VEGF Inhibitors for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 65. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021-2026) Table 66. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2027-2032) Table 67. Amgen Company Information Table 68. Amgen Business Overview Table 69. Amgen VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Amgen VEGF Inhibitors for Cancer Product Portfolio Table 71. Amgen Recent Development Table 72. Amneal Pharmaceuticals Company Information Table 73. Amneal Pharmaceuticals Business Overview Table 74. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio Table 76. Amneal Pharmaceuticals Recent Development Table 77. Celltrion Healthcare Company Information Table 78. Celltrion Healthcare Business Overview Table 79. Celltrion Healthcare VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio Table 81. Celltrion Healthcare Recent Development Table 82. Eli Lilly Company Information Table 83. Eli Lilly Business Overview Table 84. Eli Lilly VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Eli Lilly VEGF Inhibitors for Cancer Product Portfolio Table 86. Eli Lilly Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Pfizer VEGF Inhibitors for Cancer Product Portfolio Table 91. Pfizer Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Roche VEGF Inhibitors for Cancer Product Portfolio Table 96. Roche Recent Development Table 97. Sanofi Company Information Table 98. Sanofi Business Overview Table 99. Sanofi VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Sanofi VEGF Inhibitors for Cancer Product Portfolio Table 101. Sanofi Recent Development Table 102. Boan Biotech Company Information Table 103. Boan Biotech Business Overview Table 104. Boan Biotech VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Boan Biotech VEGF Inhibitors for Cancer Product Portfolio Table 106. Boan Biotech Recent Development Table 107. Jiangsu Hengrui Pharmaceuticals Company Information Table 108. Jiangsu Hengrui Pharmaceuticals Business Overview Table 109. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio Table 111. Jiangsu Hengrui Pharmaceuticals Recent Development Table 112. Qilu Pharma Company Information Table 113. Qilu Pharma Business Overview Table 114. Qilu Pharma VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio Table 116. Qilu Pharma Recent Development Table 117. SinoCellTech Company Information Table 118. SinoCellTech Business Overview Table 119. SinoCellTech VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. SinoCellTech VEGF Inhibitors for Cancer Product Portfolio Table 121. SinoCellTech Recent Development Table 122. Innovent Company Information Table 123. Innovent Business Overview Table 124. Innovent VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Innovent VEGF Inhibitors for Cancer Product Portfolio Table 126. Innovent Recent Development Table 127. Chia Tai Tianqing Company Information Table 128. Chia Tai Tianqing Business Overview Table 129. Chia Tai Tianqing VEGF Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio Table 131. Chia Tai Tianqing Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. VEGF Inhibitors for Cancer Distributors List Table 135. VEGF Inhibitors for Cancer Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. VEGF Inhibitors for Cancer Product Image Figure 2. Global VEGF Inhibitors for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGF Inhibitors for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global VEGF Inhibitors for Cancer Sales (2021-2032) & (K Units) Figure 5. Global VEGF Inhibitors for Cancer Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 VEGF Inhibitors for Cancer Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ramucirumab Image Figure 9. Ramucirumab Image Figure 10. Aflibercept Image Figure 11. Other Image Figure 12. Global VEGF Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global VEGF Inhibitors for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2032) Figure 15. Global VEGF Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global VEGF Inhibitors for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2032) Figure 18. Metastatic colorectal cancer Image Figure 19. Metastatic Non-small Cell Lung Cancer Image Figure 20. Cervical Cancer Image Figure 21. Recurrent Glioblastoma Image Figure 22. Other Image Figure 23. Global VEGF Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global VEGF Inhibitors for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2032) Figure 26. Global VEGF Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global VEGF Inhibitors for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2032) Figure 29. North America VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 31. U.S. VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 36. Germany VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 43. China VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa VEGF Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 51. Brazil VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile VEGF Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global VEGF Inhibitors for Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global VEGF Inhibitors for Cancer Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 62. North America VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 64. Europe VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. VEGF Inhibitors for Cancer Value Chain Figure 70. Manufacturing Cost Structure Figure 71. VEGF Inhibitors for Cancer Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Ramucirumab
  • Ramucirumab
  • Aflibercept
  • Other
Applications
  • Metastatic colorectal cancer
  • Metastatic Non-small Cell Lung Cancer
  • Cervical Cancer
  • Recurrent Glioblastoma
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals
  • Celltrion Healthcare
  • Eli Lilly
  • Pfizer
  • Roche
  • Sanofi
  • Boan Biotech
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global VEGF Inhibitors for Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global VEGF Inhibitors for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global VEGF Inhibitors for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global VEGF Inhibitors for Cancer Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global VEGF Inhibitors for Cancer Market Dynamics
  1. 2.1 VEGF Inhibitors for Cancer Industry Trends
  2. 2.2 VEGF Inhibitors for Cancer Industry Drivers
  3. 2.3 VEGF Inhibitors for Cancer Industry Opportunities and Challenges
  4. 2.4 VEGF Inhibitors for Cancer Industry Restraints
3 VEGF Inhibitors for Cancer Market by Manufacturers
  1. 3.1 Global VEGF Inhibitors for Cancer Revenue by Manufacturers (2021-2026)
  2. 3.2 Global VEGF Inhibitors for Cancer Sales by Manufacturers (2021-2026)
  3. 3.3 Global VEGF Inhibitors for Cancer Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global VEGF Inhibitors for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global VEGF Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global VEGF Inhibitors for Cancer Manufacturers, Product Type & Application
  7. 3.7 Global VEGF Inhibitors for Cancer Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global VEGF Inhibitors for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 VEGF Inhibitors for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 VEGF Inhibitors for Cancer Tier 1, Tier 2, and Tier 3
4 VEGF Inhibitors for Cancer Market by Type
  1. 4.1 VEGF Inhibitors for Cancer Type Introduction
  2. 4.1.1 Ramucirumab
  3. 4.1.2 Ramucirumab
  4. 4.1.3 Aflibercept
  5. 4.1.4 Other
  6. 4.2 Global VEGF Inhibitors for Cancer Sales by Type
  7. 4.2.1 Global VEGF Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  9. 4.2.3 Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2032)
  10. 4.3 Global VEGF Inhibitors for Cancer Revenue by Type
  11. 4.3.1 Global VEGF Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  13. 4.3.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2032)
5 VEGF Inhibitors for Cancer Market by Application
  1. 5.1 VEGF Inhibitors for Cancer Application Introduction
  2. 5.1.1 Metastatic colorectal cancer
  3. 5.1.2 Metastatic Non-small Cell Lung Cancer
  4. 5.1.3 Cervical Cancer
  5. 5.1.4 Recurrent Glioblastoma
  6. 5.1.5 Other
  7. 5.2 Global VEGF Inhibitors for Cancer Sales by Application
  8. 5.2.1 Global VEGF Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  10. 5.2.3 Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2032)
  11. 5.3 Global VEGF Inhibitors for Cancer Revenue by Application
  12. 5.3.1 Global VEGF Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  14. 5.3.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2032)
6 Global VEGF Inhibitors for Cancer Sales by Region
  1. 6.1 Global VEGF Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VEGF Inhibitors for Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global VEGF Inhibitors for Cancer Sales by Region (2021-2026)
  4. 6.2.2 Global VEGF Inhibitors for Cancer Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa VEGF Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global VEGF Inhibitors for Cancer Revenue by Region
  1. 7.1 Global VEGF Inhibitors for Cancer Revenue by Region
  2. 7.1.1 Global VEGF Inhibitors for Cancer Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global VEGF Inhibitors for Cancer Revenue by Region (2021-2026)
  4. 7.1.3 Global VEGF Inhibitors for Cancer Revenue by Region (2027-2032)
  5. 7.1.4 Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America VEGF Inhibitors for Cancer Revenue (2021-2032)
  8. 7.2.2 North America VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe VEGF Inhibitors for Cancer Revenue (2021-2032)
  11. 7.3.2 Europe VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific VEGF Inhibitors for Cancer Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa VEGF Inhibitors for Cancer Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa VEGF Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen VEGF Inhibitors for Cancer Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Amneal Pharmaceuticals
  8. 8.2.1 Amneal Pharmaceuticals Company Information
  9. 8.2.2 Amneal Pharmaceuticals Business Overview
  10. 8.2.3 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals Recent Developments
  13. 8.3 Celltrion Healthcare
  14. 8.3.1 Celltrion Healthcare Company Information
  15. 8.3.2 Celltrion Healthcare Business Overview
  16. 8.3.3 Celltrion Healthcare VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio
  18. 8.3.5 Celltrion Healthcare Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly VEGF Inhibitors for Cancer Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer VEGF Inhibitors for Cancer Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche VEGF Inhibitors for Cancer Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi VEGF Inhibitors for Cancer Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
  43. 8.8 Boan Biotech
  44. 8.8.1 Boan Biotech Company Information
  45. 8.8.2 Boan Biotech Business Overview
  46. 8.8.3 Boan Biotech VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boan Biotech VEGF Inhibitors for Cancer Product Portfolio
  48. 8.8.5 Boan Biotech Recent Developments
  49. 8.9 Jiangsu Hengrui Pharmaceuticals
  50. 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Qilu Pharma
  56. 8.10.1 Qilu Pharma Company Information
  57. 8.10.2 Qilu Pharma Business Overview
  58. 8.10.3 Qilu Pharma VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio
  60. 8.10.5 Qilu Pharma Recent Developments
  61. 8.11 SinoCellTech
  62. 8.11.1 SinoCellTech Company Information
  63. 8.11.2 SinoCellTech Business Overview
  64. 8.11.3 SinoCellTech VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 SinoCellTech VEGF Inhibitors for Cancer Product Portfolio
  66. 8.11.5 SinoCellTech Recent Developments
  67. 8.12 Innovent
  68. 8.12.1 Innovent Company Information
  69. 8.12.2 Innovent Business Overview
  70. 8.12.3 Innovent VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Innovent VEGF Inhibitors for Cancer Product Portfolio
  72. 8.12.5 Innovent Recent Developments
  73. 8.13 Chia Tai Tianqing
  74. 8.13.1 Chia Tai Tianqing Company Information
  75. 8.13.2 Chia Tai Tianqing Business Overview
  76. 8.13.3 Chia Tai Tianqing VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio
  78. 8.13.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VEGF Inhibitors for Cancer Value Chain Analysis
  2. 9.1.1 VEGF Inhibitors for Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VEGF Inhibitors for Cancer Production Mode & Process
  6. 9.2 VEGF Inhibitors for Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VEGF Inhibitors for Cancer Distributors
  9. 9.2.3 VEGF Inhibitors for Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst